Trial Profile
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Brigatinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors ARIAD Pharmaceuticals; Takeda Pharma
- 08 Jun 2021 Final results of long-term efficacy and safety of the phase 1/2 and phase 2 trials (NCT01449461, NCT02094573) of BRG presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 20 Aug 2020 Results (n=442) of population pharmacokinetics model based analysis from five clinical studies: ATLAS, AP26113-13-102, AP26113-13-103, AP26113-15-105 and NCT01449461published in the Clinical Pharmacokinetics
- 02 Mar 2020 Results of phase 1-3 studies (phase 1/2, ALTA, and ALTA-1L) assessing early-onset pulmonary events after drug administration, published in the Journal of Thoracic Oncology.